204 related articles for article (PubMed ID: 22145213)
1. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
3.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
4. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
Molinari F; Martin V; Saletti P; De Dosso S; Spitale A; Camponovo A; Bordoni A; Crippa S; Mazzucchelli L; Frattini M
Br J Cancer; 2009 Apr; 100(7):1087-94. PubMed ID: 19293803
[TBL] [Abstract][Full Text] [Related]
5. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Smith CG; Fisher D; Claes B; Maughan TS; Idziaszczyk S; Peuteman G; Harris R; James MD; Meade A; Jasani B; Adams RA; Kenny S; Kaplan R; Lambrechts D; Cheadle JP
Clin Cancer Res; 2013 Aug; 19(15):4104-13. PubMed ID: 23741067
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
Eng C
Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
[TBL] [Abstract][Full Text] [Related]
9. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
Raghav KP; Shetty AV; Kazmi SM; Zhang N; Morris J; Taggart M; Fournier K; Royal R; Mansfield P; Eng C; Wolff RA; Overman MJ
Oncologist; 2013; 18(12):1270-7. PubMed ID: 24149137
[TBL] [Abstract][Full Text] [Related]
10. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
De Stefano A; Carlomagno C
World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.
Di Fiore F; Sesboüé R; Michel P; Sabourin JC; Frebourg T
Br J Cancer; 2010 Dec; 103(12):1765-72. PubMed ID: 21139621
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M
BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446
[TBL] [Abstract][Full Text] [Related]
13. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
14. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
Blanke CD; Goldberg RM; Grothey A; Mooney M; Roach N; Saltz LB; Welch JJ; Wood WA; Meropol NJ;
Oncologist; 2011; 16(8):1061-8. PubMed ID: 21737577
[TBL] [Abstract][Full Text] [Related]
15. Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R.
Chen R; Yang D; Liu Y; Wang B; Xu H
Anticancer Drugs; 2024 Feb; 35(2):195-198. PubMed ID: 38018809
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and biomarkers in colorectal cancer.
Grady WM; Pritchard CC
Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
[TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
[TBL] [Abstract][Full Text] [Related]
19. A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells.
Landi N; Ciaramella V; Ragucci S; Chambery A; Ciardiello F; Pedone PV; Troiani T; Di Maro A
Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668877
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
Lin JS; Webber EM; Senger CA; Holmes RS; Whitlock EP
Am J Cancer Res; 2011 May; 1(5):650-62. PubMed ID: 21779535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]